WCG acquires biostatistical consultancy Statistics Collaborative

WIRB-Copernicus Group, a Princeton-based provider of solutions for clinical research, announced on Thursday it has acquired Statistics Collaborative Inc.

Based in Washington, D.C., Statistics Collaborative provides biostatistical consulting services to developers of new drugs and biologics.

“WCG seeks to partner with outstanding companies who share our vision for improving the clinical trial process, while maintaining the highest scientific and ethical standards. We quickly recognized Statistics Collaborative as a company with a similar work ethic, employee culture, and industry goals. Statistics Collaborative’s exceptional reputation as a leader in biostatistical analysis and consulting for pharmaceutical and biotechnology companies made it a treasured partner to welcome into WCG,” Donald A. Deieso, executive chairman and CEO of WCG, said.

All of the staff from Statistics Collaborative will join WCG and its leadership will remain unchanged. The company will also retain its headquarters in D.C.

“We are delighted to be joining WCG. Statistics Collaborative had reached an inflection point in our growth. We were looking for a like-minded partner organization, which could provide the requisite resources and infrastructure that would allow our company to continue to evolve while retaining our position as a premier biostatistics partner to the biopharmaceutical industry. We felt that WCG was a good cultural fit for our company. WCG puts the same emphasis on scientific rigor and integrity, and it puts people first – not just patients and clients, but employees, as well. It significantly invests in employee professional development,” Janet Wittes, founder and president, Statistics Collaborative, said. “Statistics Collaborative will continue to provide the same services and deliverables, but with the benefit of additional financial resources and powerful operations and technology platforms that complement our business.”

WCG will provide Statistics Collaborative with access to capital, it said, clinical development experts and operational support. Going forward, the company will be known as WCG Statistics Collaborative and will be part of WCG’s Scientific and Regulatory Review division.

Financial terms were not disclosed.